The U.S. Food and Drug Administration on Friday authorized two COVID-19 vaccines for children aged 5 and under, opening the door to vaccinating millions of the country’s youngest children.
A look at some of the latest COVID-19 news includes the U.S. Food and Drug Administration’s plans to review changes to Novavax’s manufacturing process before the regulatory agency authorizes the company’s vaccine. Moderna expects to submit data to regulators soon with expectations of the company’s bivalent COVID-19 vaccine—consisting of the original Spikevax vaccine and a newer version, mRNA-1273.214 that contains an Omicron-specific vaccine—becoming available in late summer.
The BA.4 and BA.5 sub-variants of Omicron are estimated to make up nearly 5% and 8% of the coronavirus variants in the United States as of June 4, the U.S. Centers for Disease Control and Prevention (CDC) said on Tuesday.
Pfizer Inc. and partner BioNTech completed the filing with the U.S. drugs regulator seeking authorization for their COVID-19 vaccine in children under 5 years of age.
Patients who experience recurrence of COVID-19 symptoms after completing treatment with Pfizer’s drug Paxlovid should isolate again for five days, the U.S. Centers for Disease Control and Prevention said in an advisory issued on Tuesday.
A global health fund has raised a third of the $18 billion it says is needed to reverse setbacks caused by the coronavirus pandemic and combat AIDS, malaria, and tuberculosis.
Drugmakers Pfizer Inc and BioNTech SE said on May 23 that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.
North Korea on May 21 reported more than 200,000 new patients suffering from fever for a fifth consecutive day, as the country fought its first confirmed coronavirus outbreak.